Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

Pfizer plans to acquire ReViral and its respiratory syncytial virus therapeutic candidates to strengthen Pfizer’s capabilities in infectious disease research.